Preclinical Data on the Potential of Byondis ADC BYON3521 Published in Molecular Cancer Therapeutics

/PRNewswire/ -- Byondis B.V., an independent, clinical-stage Dutch biopharmaceutical company creating precision medicines, today announced that Molecular...

Related Keywords

Italy ,United Kingdom ,Belgium ,United States ,Netherlands ,Nijmegen ,Gelderland ,Dutch ,American ,Wim Dokter ,Prnewswire Byondis ,Conjugation Technology ,First In Human Study ,Molecular Cancer Therapeutics ,American Association ,Cancer Research ,Byondis Chief Scientific Officer Wim Dokter ,Next Generation Antibody Drug ,Proprietary Linker Drug ,Site Specific Conjugation ,Good Manufacturing Practice ,Byondisbv ,